US EditionNasal COVID Vax Shows Promise in Phase 1 Clinical Trial
- A nasal vaccine could be more effective and tolerable for children and adults afraid of needles.
- Participants who received the highest dose of CVXGA showed significantly lower rates of symptomatic COVID-19 infection.
- The vaccine produced a mucosal antibody response rate of 51.9% in higher dose groups, compared to 21.4% in lower dose groups.
- Based on phase 1 trial data, two larger clinical studies are currently underway.
29 Articles
29 Articles
Rutland Herald
Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial
CINCINNATI, July 4, 2025 /PRNewswire/ -- During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus invading the nasal tissues of its victims, then causing millions of deaths by spreading through the body…
Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial - PressReach
CINCINNATI, July 4, 2025 /PRNewswire/ — During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus invading the nasal tissues of its victims, then causing millions of deaths by spreading through the body and robbing the sickest people of their ability to breathe. While the traditional way to administer protection has been to inject vaccines into the bloodstream, many experts called for…
Coverage Details
Bias Distribution
- 56% of the sources are Center
To view factuality data please Upgrade to Premium
